Researchers at the University of Virginia School of Medicine have identified an unexpected contributor to rheumatoid arthritis that may help explain the painful flare-ups associated with the disease. The discovery points to a potential new treatment for the autoimmune disorder and may also allow the use of a simple blood test to detect people at elevated risk for developing the condition.
The promising discovery is among the first to emerge from the School of Medicine’s new affiliation with Inova Health, a collaboration that aims to make medical breakthroughs and advance the battle against disease. In this case, the arthritis discovery originated in the lab of UVA’s Kodi Ravichandran, PhD, and was facilitated by combining his team’s resources and expertise with that of Inova researcher Thomas Conrads, PhD, through a THRIV UVA-Inova seed grant.
Understanding Rheumatoid Arthritis
The new findings about rheumatoid arthritis came in an unexpected fashion. Sanja Arandjelovic, PhD, a research scientist in the Ravichandran group, was seeking to better understand what causes the inflammation associated with inflammatory arthritis when she noted that deleting a gene called ELMO1 alleviated arthritis symptoms in mice. This was particularly surprising because Arandjelovic and Ravichandran initially thought that loss of ELMO1 would result in increased inflammation.
“This was a complete surprise to us initially,” recalled Ravichandran, chairman of UVA’s Department of Microbiology, Immunology and Cancer Biology. “I love those kinds of results, because they tell us that, first, we did not fully comprehend the scientific problem when we began exploring it, and, second, such unexpected results challenge us to think in a different way. Given that rheumatoid arthritis affects millions of people worldwide, we felt the need to understand this observation better.”
Digging deeper into the unusual outcome, the researchers determined that ELMO1 promotes inflammation via their function in white blood cells called neutrophils. Ravichandran described neutrophils as the body’s “first line of defense” because they sense and respond to potential threats. “Normally they are good for us, against many bacterial infections,” he said. “But also there are many times when they produce a lot of friendly fire that is quite damaging to the tissues – when they hang around too long or there are too many neutrophils coming in – in this case, infiltrating into the joints during arthritis.”
The researchers also discovered that there is a natural variation in the ELMO1 gene that can prompt neutrophils to become more mobile and have the potential to invade the joints in greater numbers and induce inflammation. (The potential blood test would detect this variation.)
Here things take a particularly cool turn: Normally, doctors are reluctant to try to block the effect of genes like ELMO1 in people, because such genes can play diverse roles in the body. But Ravichandran believes that ELMO1 is different. “ELMO1 partners with very specific set of proteins only in the neutrophils but not in other cells types we tested,” he said. “So, presumably, you may be able to affect only a select cell type.” This latter result came about from a collaborative study where Conrads’ group at Inova performed sophisticated analysis of ELMO1 proteomic partners in neutrophils, many of which also have previously known links to human arthritis. This provided further validation for the role of ELMO1 in rheumatoid arthritis.
Encouragingly, blocking ELMO1 in lab mice alleviated arthritis inflammation without causing other problems, Ravichandran noted. His laboratory is now seeking to identify drugs that could inhibit the function of ELMO1 and is also designing a test for the variation (also called polymorphism) in the ELMO1 gene.
“This is another example of how fundamental basic research can lead to novel discoveries on clinically relevant problems that affect a large number of people,” Ravichandran said.
The Latest on: Rheumatoid arthritis
via Google News
The Latest on: Rheumatoid arthritis
- New Research Among People Living With Rheumatoid Arthritis Reveals Key Determinants Of Patient Satisfaction With Doctorson March 20, 2020 at 9:57 am
/PRNewswire/ -- MyHealthTeams, creator of the largest and fastest-growing social networks for people facing chronic health conditions, today unveiled ...
- Arthritis drug answer to pregnancy malaria, study findson March 20, 2020 at 7:16 am
The new study, published in Science Advances, found that the drug Anakinra restored fetal growth and reduced deaths in an experimental model. Anakinra is commonly used to treat rheumatoid arthritis ...
- Drugs for Rheumatoid Arthritis Market Research Report 2020: Global Market Size By Players, Regions, Type, Application Forecast To 2026on March 19, 2020 at 10:32 pm
Drugs for Rheumatoid Arthritis Market” 2020-2026 describes a detailed evaluation and proficient study on the current and future state of the Drugs for Rheumatoid Arthritis market across the globe, ...
- Genentech arthritis drug to be tested against COVID-19on March 19, 2020 at 12:19 pm
Biotech giant Genentech Inc. is working with federal agencies to start a late-stage clinical trial in early April of its already-approved rheumatoid arthritis drug Actemra against the virus that ...
- Regeneron to treat coronavirus patients this week in trial using its rheumatoid arthritis drugon March 18, 2020 at 5:28 pm
"This could in a very short time give hope to the most critical people," Regeneron Chief Scientific Officer Dr. George Yancopoulos told CNBC.
- Rheumatoid Arthritis Drugs Market To Reach USD 36.11 Billion By 2027on March 18, 2020 at 6:46 am
The Global Rheumatoid Arthritis Drugs Market is forecast to reach USD 36.11 Billion by 2027, according to a new report by Reports and Data. Rheumatoid arthritis is an inflammatory disease that affects ...
- Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Periodon March 18, 2020 at 3:00 am
/PRNewswire/ -- The global Rheumatoid Arthritis market is estimated to have reached $58bn in 2018 and is expected to grow at a CAGR of 0.6% in the second ...
- Living with Rheumatoid Arthritison March 12, 2020 at 5:13 am
A physical therapist or sports medicine specialist may be able to offer advice to patients who wish to participate in a sport or physical activity but require modifications or assistive devices ...
- Identification of highly potent and selective inhibitor, TIPTP, of the p22phox-Rubicon axis as a therapeutic agent for rheumatoid arthritison March 12, 2020 at 3:08 am
LPS (Escherichia coli O111:B4) and ATP were purchased from Sigma. Specific antibodies against Rubicon (ab92388) were purchased from Abcam. Antibodies against Beclin-1 (3738) and UVRAG (5320) were ...
- People with Rheumatoid Arthritis Have Higher Risk for Heart Diseaseon March 9, 2020 at 3:24 pm
Share on Pinterest Researchers and experts say people with rheumatoid arthritis are more likely to have major cardiovascular events, such as stroke and heart attack. Getty Images A new study says ...
via Bing News